AMENDMENT CONSENTBema License Agreement • January 6th, 2009 • Biodelivery Sciences International Inc • Pharmaceutical preparations • North Carolina
This AMENDMENT CONSENT (the “Consent”) is entered this January 2, 2009 (the “Consent Date”) by Arius Pharmaceuticals, Inc. (“Arius”) and Arius Two, Inc. (“Arius Two”).
AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • January 6th, 2009 • Biodelivery Sciences International Inc • Pharmaceutical preparations • New York
This AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENT (the “Amendment”) is entered this January 2, 2008 (the “Amendment Date”), by BioDelivery Sciences International, Inc., a Delaware corporation with offices at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607 (“Parent”), its wholly-owned subsidiary Arius Pharmaceuticals, Inc., a Delaware corporation with offices at the same address (“Arius”, and together with Parent, “BDSI”) and Meda AB, a Swedish corporation located at Pipers väg 2 A, SE-170 09, Solna, Sweden (“Meda”),
CONSENT AGREEMENTConsent Agreement • January 6th, 2009 • Biodelivery Sciences International Inc • Pharmaceutical preparations • New York
This CONSENT AGREEMENT (the “Consent”) is entered this January 2, 2009, by BioDelivery Sciences International, Inc., with offices at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607, its wholly-owned subsidiary Arius Pharmaceuticals, Inc., with offices at the same address (“Arius”; with Parent, “BDSI”), and CDC IV, LLC, with offices at 47 Hulfish Street, Suite 310, Princeton, New Jersey 08542 (“CDC”).
AMENDMENT CONSENTBema License Agreement • January 6th, 2009 • Biodelivery Sciences International Inc • Pharmaceutical preparations • North Carolina
This AMENDMENT CONSENT (the “Consent”) is entered this January 2, 2009 (the “Consent Date”) by Arius Pharmaceuticals, Inc. (“Arius”) and Arius Two, Inc. (“Arius Two”).
